{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:12:10Z","timestamp":1775059930002,"version":"3.50.1"},"reference-count":45,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Cycle"],"published-print":{"date-parts":[[2013,6,15]]},"DOI":"10.4161\/cc.24928","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T14:57:07Z","timestamp":1371481027000},"page":"1892-1900","source":"Crossref","is-referenced-by-count":65,"title":["Induction of prolonged early G<sub>1<\/sub>arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1"],"prefix":"10.1080","volume":"12","author":[{"given":"David","family":"Chiron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Di Liberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Ely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,11,5]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"R2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","article-title":"PI3K\u03b4 inhibitors in cancer: rationale and serendipity merge in the clinic","volume":"1","author":"Fruman","year":"2011","journal-title":"Cancer Discov"},{"key":"R3","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"R5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"R6","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"R7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"key":"R9","unstructured":"Kahl BBJ, Flinn IW, et al. Clinical Safety and Activity In a Phase1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2010; 116:1777."},{"key":"R10","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdn193","article-title":"Current treatment standards and future strategies in mantle cell lymphoma","volume":"19","author":"Dreyling","year":"2008","journal-title":"Ann Oncol"},{"key":"R11","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/0008-5472.CAN-04-1526","article-title":"CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a\/ARF locus","volume":"65","author":"Hern\u00e1ndez","year":"2005","journal-title":"Cancer Res"},{"key":"R12","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood.V99.12.4554","article-title":"Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes","volume":"99","author":"Korz","year":"2002","journal-title":"Blood"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev"},{"key":"R14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"R16","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"key":"R17","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"R18","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"R19","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res"},{"key":"R20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3:CDK4\/6 complex in T cell leukemia","volume":"22","author":"Sawai","year":"2012","journal-title":"Cancer Cell"},{"key":"R21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"R22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"R23","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.21195","article-title":"Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors","volume":"11","author":"Dean","year":"2012","journal-title":"Cell Cycle"},{"key":"R24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged early G(1) arrest by selective CDK4\/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"R25","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"R26","first-page":"4","volume":"3","author":"CDK Inhibitor Triples PFS in Breast Cancer","year":"2013","journal-title":"Cancer Discov"},{"key":"R27","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/onc.2011.414","article-title":"Differential roles for the p101 and p84 regulatory subunits of PI3Kgamma in tumor growth and metastasis","volume":"31","author":"Brazzatti","year":"2012","journal-title":"Oncogene"},{"key":"R28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2005.05784.x","article-title":"Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia","volume":"131","author":"Bousquet","year":"2005","journal-title":"Br J Haematol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"R30","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"R31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2010-06-288027","article-title":"Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors","volume":"117","author":"Bretz","year":"2011","journal-title":"Blood"},{"key":"R32","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"R33","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"key":"R34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2007.04.096","article-title":"PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein","volume":"358","author":"Zhu","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med"},{"key":"R36","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"R37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.726","article-title":"Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells","volume":"3","author":"Sander","year":"2012","journal-title":"Oncotarget"},{"key":"R39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.18632\/oncotarget.341","article-title":"Phosphoinositide 3\u2032-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia","volume":"2","author":"Burger","year":"2011","journal-title":"Oncotarget"},{"key":"R40","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4161\/cc.21127","article-title":"CDK4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy","volume":"11","author":"McClendon","year":"2012","journal-title":"Cell Cycle"},{"key":"R41","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/0008-5472.CAN-08-0025","article-title":"PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma","volume":"68","author":"He","year":"2008","journal-title":"Cancer Res"},{"key":"R42","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/eji.201141653","article-title":"Inhibition of T-cell activation by PIK3IP1","volume":"42","author":"DeFrances","year":"2012","journal-title":"Eur J Immunol"},{"key":"R43","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1096\/fj.12-208587","article-title":"Expression of constitutively active FoxO3 in murine forebrain leads to a loss of neural progenitors","volume":"26","author":"Schmidt-Strassburger","year":"2012","journal-title":"FASEB J"},{"key":"R44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R45","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1101\/gr.078212.108","article-title":"Mapping short DNA sequencing reads and calling variants using mapping quality scores","volume":"18","author":"Li","year":"2008","journal-title":"Genome Res"}],"container-title":["Cell Cycle"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/cc.24928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T12:17:43Z","timestamp":1688300263000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/cc.24928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,15]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,5]]},"published-print":{"date-parts":[[2013,6,15]]}},"alternative-id":["10.4161\/cc.24928"],"URL":"https:\/\/doi.org\/10.4161\/cc.24928","relation":{},"ISSN":["1538-4101","1551-4005"],"issn-type":[{"value":"1538-4101","type":"print"},{"value":"1551-4005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,15]]}}}